

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Krishna Murthi</td> <td>08/19/2009</td> </tr> <tr> <td>Rebecca Casaubon</td> <td>08/20/2009</td> </tr> <tr> <td>Arthur F Kluge</td> <td>09/03/2009</td> </tr> <tr> <td>Chase C Smith</td> <td>09/03/2009</td> </tr> </tbody> </table>		Name	Execution Date	Krishna Murthi	08/19/2009	Rebecca Casaubon	08/20/2009	Arthur F Kluge	09/03/2009	Chase C Smith	09/03/2009
Name	Execution Date										
Krishna Murthi	08/19/2009										
Rebecca Casaubon	08/20/2009										
Arthur F Kluge	09/03/2009										
Chase C Smith	09/03/2009										
RECEIVING PARTY DATA											
<table border="1"> <tr> <td>Name:</td> <td>GPC Biotech AG</td> </tr> <tr> <td>Street Address:</td> <td>Fraunhoferstr. 20</td> </tr> <tr> <td>City:</td> <td>Martinsried/Munich</td> </tr> <tr> <td>State/Country:</td> <td>GERMANY</td> </tr> <tr> <td>Postal Code:</td> <td>82152</td> </tr> </table>		Name:	GPC Biotech AG	Street Address:	Fraunhoferstr. 20	City:	Martinsried/Munich	State/Country:	GERMANY	Postal Code:	82152
Name:	GPC Biotech AG										
Street Address:	Fraunhoferstr. 20										
City:	Martinsried/Munich										
State/Country:	GERMANY										
Postal Code:	82152										
<table border="1"> <tr> <td>Name:</td> <td>GPC Biotech Inc</td> </tr> <tr> <td>Street Address:</td> <td>101 College Road East</td> </tr> <tr> <td>City:</td> <td>Princeton</td> </tr> <tr> <td>State/Country:</td> <td>NEW JERSEY</td> </tr> <tr> <td>Postal Code:</td> <td>08540</td> </tr> </table>		Name:	GPC Biotech Inc	Street Address:	101 College Road East	City:	Princeton	State/Country:	NEW JERSEY	Postal Code:	08540
Name:	GPC Biotech Inc										
Street Address:	101 College Road East										
City:	Princeton										
State/Country:	NEW JERSEY										
Postal Code:	08540										
PROPERTY NUMBERS Total: 1											
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13105957</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13105957						
Property Type	Number										
Application Number:	13105957										
CORRESPONDENCE DATA											
Fax Number:	(908)273-0711										
Email:	paralegal@gearhartlaw.com										
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>											
Correspondent Name:	Richard Gearhart, Esq.										
Address Line 1:	41 River Rd										

OP \$40.00 13105957

Address Line 4: Summit, NEW JERSEY 07901

NAME OF SUBMITTER:

Richard Gearhart

Total Attachments: 15

source=IPD-220_Casaubon_Assignment#page1.tif

source=IPD-220_Casaubon_Assignment#page2.tif

source=IPD-220_Casaubon_Assignment#page3.tif

source=IPD-220_KlugeSmith_Assignment#page1.tif

source=IPD-220_KlugeSmith_Assignment#page2.tif

source=IPD-220_KlugeSmith_Assignment#page3.tif

source=IPD-220_Murthi_Assignment#page1.tif

source=IPD-220_Murthi_Assignment#page2.tif

source=IPD-220_Murthi_Assignment#page3.tif

source=statementsexecuted#page1.tif

source=statementsexecuted#page2.tif

source=statementsexecuted#page3.tif

source=statementsexecuted#page4.tif

source=statementsexecuted#page5.tif

source=statementsexecuted#page6.tif

ASSIGNMENT

WE, each of the Undersigned, **Krishna K. Murthi, Rebecca Casaubon, Arthur F. Kluge, and Chase C. Smith**, for good and valuable consideration, the receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to **GPC Biotech Inc. and GPC Biotech AG**, organisations respectively existing under the State of Delaware and Germany and respectively having offices and place of businesses at 101 College Road East, Princeton, NJ 08540 USA, and Fraunhoferstrasse 20, 82152 Planegg (Martinsried)/Munich Germany, their successors and assigns (together, GPC Biotech Inc. and GPC Biotech AG "ASSIGNEE"):

1) the entire right, title and interest in the United States and in all countries throughout the world in and to any and all my inventions and discoveries disclosed in the patent applications entitled:

Improved Raf Inhibitors

• State	Appl. No.	Appl. Date
• EP	08103665.9	22-Apr-2008
• PCT	PCT/EP2009/002930	21-Apr-2009;

including any renewals, revivals, reissues, reexaminations, extensions, continuations, continuations-in-part, and divisions thereof, and any substitute applications therefor;

2) the full and complete right to file patent applications in the name of ASSIGNEE, its designee, or in my name at the election of ASSIGNEE or its designee, on the aforesaid inventions, discoveries and applications in all countries of the world;

3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any other country of the world and any renewals, revivals, reissues, reexaminations and extensions of the same; and

4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

I hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to ASSIGNEE as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed, by me had this assignment, sale and transfer not been made.

I agree, at any time, upon the request of ASSIGNEE, to execute and to deliver to ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, continuations-in-part, renewals, revivals, reissues, reexaminations and extensions thereof.

I further agree at any time to execute and to deliver upon request of ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNOR:

DATE OF SIGNING:

WITNESSED BY:

Krishna K. Murthi

Date

Witness:

 8/20/2009

Rebecca Casaubon

Date



Witness: Charles Blum

Arthur F. Kluge

Date

Witness:

Chase C. Smith

Date

Witness:

ACKNOWLEDGMENT OF ASSIGNEE:

The undersigned, officers duly empowered to acknowledge documents of this sort on behalf of GPC Biotech Inc. and GPC Biotech AG respectively, hereby acknowledge the foregoing executed Assignment on behalf of the ASSIGNEE.


For: GPC Biotech Inc. and GPC Biotech AG

ASSIGNEE:

DATE OF SIGNING:

WITNESSED BY:

FOR GPC Biotech AG:



Name:

Dr. Torsten Hombeck

8/31/2009


Date



Witness:

Rebecca Regan

FOR GPC Biotech Inc.:



Name:

9-2-09

Date



Witness:

Rebecca Regan

ASSIGNMENT

WE, each of the Undersigned, **Krishna K. Murthi, Rebecca Casaubon, Arthur F. Kluge, and Chase C. Smith**, for good and valuable consideration, the receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to **GPC Biotech Inc.** and **GPC Biotech AG**, organisations respectively existing under the State of Delaware and Germany and respectively having offices and place of businesses at 101 College Road East, Princeton, NJ 08540 USA, and Fraunhoferstrasse 20, 82152 Planegg (Martinsried)/Munich Germany, their successors and assigns (together, GPC Biotech Inc. and GPC Biotech AG "ASSIGNEE"):

1) the entire right, title and interest in the United States and in all countries throughout the world in and to any and all my inventions and discoveries disclosed in the patent applications entitled:

Improved Raf Inhibitors

• State	Appl. No.	Appl. Date
• EP	08103665.9	22-Apr-2008
• PCT	PCT/EP2009/002930	21-Apr-2009;

including any renewals, revivals, reissues, reexaminations, extensions, continuations, continuations-in-part, and divisions thereof, and any substitute applications therefor;

2) the full and complete right to file patent applications in the name of ASSIGNEE, its designee, or in my name at the election of ASSIGNEE or its designee, on the aforesaid inventions, discoveries and applications in all countries of the world;

3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any other country of the world and any renewals, revivals, reissues, reexaminations and extensions of the same; and

4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

I hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to ASSIGNEE as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed, by me had this assignment, sale and transfer not been made.

I agree, at any time, upon the request of ASSIGNEE, to execute and to deliver to ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, continuations-in-part, renewals, revivals, reissues, reexaminations and extensions thereof.

I further agree at any time to execute and to deliver upon request of ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNOR:

DATE OF SIGNING:

WITNESSED BY:

Krishna K. Murthi

Date

Witness:

Rebecca Casaubon

Date

Witness:




Arthur F. Kluge

Sept. 3, 2009

Date




Witness:



Chase C. Smith

9/3/09

Date



Witness:

ACKNOWLEDGMENT OF ASSIGNEE:

The undersigned, officers duly empowered to acknowledge documents of this sort on behalf of GPC Biotech Inc. and GPC Biotech AG respectively, hereby acknowledge the foregoing executed Assignment on behalf of the ASSIGNEE.

For: GPC Biotech Inc. and GPC Biotech AG

ASSIGNEE:

DATE OF SIGNING:

WITNESSED BY:

For GPC Biotech AG:

Torsten Hombeck 9 Sept 09
Name: 9 Sept 09 Date
Torsten Hombeck

Rebecca Regan
Witness: Rebecca Regan

For GPC Biotech Inc.

Torsten Hombeck 9 Sept 09
Name: Torsten Date
Hombeck

Rebecca Regan
Witness: Rebecca Regan

ASSIGNMENT

WE, each of the Undersigned, **Krishna K. Murthi, Rebecca Casaubon, Arthur F. Kluge, and Chase C. Smith**, for good and valuable consideration, the receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to **GPC Biotech Inc. and GPC Biotech AG**, organisations respectively existing under the State of Delaware and Germany and respectively having offices and place of businesses at 101 College Road East, Princeton, NJ 08540 USA, and Fraunhoferstrasse 20, 82152 Planegg (Martinsried)/Munich Germany, their successors and assigns (together, GPC Biotech Inc. and GPC Biotech AG "ASSIGNEE"):

1) the entire right, title and interest in the United States and in all countries throughout the world in and to any and all my inventions and discoveries disclosed in the patent applications entitled:

Improved Raf Inhibitors

• State	Appl. No.	Appl. Date
• EP	08103665.9	22-Apr-2008
• PCT	PCT/EP2009/002930	21-Apr-2009;

including any renewals, revivals, reissues, reexaminations, extensions, continuations, continuations-in-part, and divisions thereof, and any substitute applications therefor;

2) the full and complete right to file patent applications in the name of ASSIGNEE, its designee, or in my name at the election of ASSIGNEE or its designee, on the aforesaid inventions, discoveries and applications in all countries of the world;

3) the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any other country of the world and any renewals, revivals, reissues, reexaminations and extensions of the same; and

4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

I hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to ASSIGNEE as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed, by me had this assignment, sale and transfer not been made.

I agree, at any time, upon the request of ASSIGNEE, to execute and to deliver to ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, continuations-in-part, renewals, revivals, reissues, reexaminations and extensions thereof.

I further agree at any time to execute and to deliver upon request of ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNOR:

DATE OF SIGNING:

WITNESSED BY:

Krishna K. Murthi

Krishna K. Murthi

8/19/09

Date

Jin J. Murthi

Witness:

Rebecca Casaubon

Rebecca Casaubon

Date

Date

Witness:

Witness:

Arthur F. Kluge

Arthur F. Kluge

Date

Date

Witness:

Witness:

Chase C. Smith

Chase C. Smith

Date

Date

Witness:

Witness:

ACKNOWLEDGMENT OF ASSIGNEE:

The undersigned, officers duly empowered to acknowledge documents of this sort on behalf of GPC Biotech Inc. and GPC Biotech AG respectively, hereby acknowledge the foregoing executed Assignment on behalf of the ASSIGNEE.


For: GPC Biotech Inc. and GPC Biotech AG

ASSIGNEE:

DATE OF SIGNING:

WITNESSED BY:


For GPC Biotech AG:




Name:

Torsten Hombeck

8/31/2009
Date


Witness: Rebecca Regan

For GPC Biotech Inc.:



Name:

Torsten Hombeck

9-2-09
Date


Witness: Rebecca Regan

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Forma Therapeutics, Inc.Application No./Patent No.: 13/105,957Filed/Issue Date: 05/12/2011

Titled:

RAF Inhibitors

Forma Therapeutics, Inc.

, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

the patent application/patent identified above, by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Andreas SchoopTo: GPC Biotech AG

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: Alexander BakesTo: GPC Biotech AG

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: Joachim VogtTo: GPC Biotech AG

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

- ☒ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Date

Steven Tregay

CEO

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2. **PATENT****REEL: 028402 FRAME: 0667**

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Forma Therapeutics, Inc.Application No./Patent No.: 13/105,957Filed/Issue Date: 05/12/2011Titled: RAF InhibitorsForma Therapeutics, Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

the patent application/patent identified above, by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Lars Neuman To: GPC Biotech AGThe document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.2. From: Jan Eickhoff To: GPC Biotech AGThe document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.3. From: Stefan Hannus To: GPC Biotech AGThe document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

- ☒ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Date

Steven Tregay

CEO

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Forma Therapeutics, Inc.Application No./Patent No.: 13/105,957Filed/Issue Date: 05/12/2011

Titled:

RAF Inhibitors

Forma Therapeutics, Inc.

, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

the patent application/patent identified above, by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Kerrin HansenTo: GPC Biotech AG

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: Peter AmonTo: GPC Biotech AG

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: Igor IvanovTo: GPC Biotech AG

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

- ☒ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Date

Steven Tregay

CEO

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2. **PATENT****REEL: 028402 FRAME: 0669**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Forma Therapeutics, Inc.Application No./Patent No.: 13/105,957Filed/Issue Date: 05/12/2011Titled: RAF InhibitorsForma Therapeutics, Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

the patent application/patent identified above, by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Matthias Borgmann To: GPC Biotech AGThe document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.2. From: Chase Smith To: GPC Biotech AG and GPC Biotech IncThe document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.3. From: Arthur F. Kluge To: GPC Biotech AG and GPC Biotech IncThe document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

- ☒ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Date

Steven Tregay

CEO

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2. **PATENT****REEL: 028402 FRAME: 0670**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Forma Therapeutics, Inc.Application No./Patent No.: 13/105,957Filed/Issue Date: 05/12/2011Titled: RAF InhibitorsForma Therapeutics, Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

the patent application/patent identified above, by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Krishna Murthi To: GPC Biotech AG and GPC Biotech Inc

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: Rebecca Casaubon To: GPC Biotech AG and GPC Biotech Inc

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: GPC Biotech AG and GPC Biotech Inc To: Forma Therapeutics, Inc.

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

- ☒ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Date

Steven Tregay

CEO

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2. **PATENT****REEL: 028402 FRAME: 0671**

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PATENT

RECORDED: 06/19/2012

REEL: 028402 FRAME: 0672